• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

June 14, 2018

View Archived Issues

Financings

Catabasis Pharmaceuticals Inc., of Cambridge, Mass, has filed its S-1A with the SEC to raise $30 million by offering 20.27 million common units consisting of one share of common stock and a warrant to purchase one share of common stock. Read More

Regulatory front

Recognizing the dire need for new antimicrobial drugs and the economic hurdles that discourage investment in the field, the FDA is looking for ways to spur antimicrobial innovation. One possibility would be to borrow a reimbursement model from the software world – paying by licensing rather than by dose. Read More

Appointments and advancements

Rani Therapeutics LLC, of San Jose, Calif., appointed Dennis (Denny) Ausiello to its board. Read More

Other news to note

Lumen Bioscience Inc., a Seattle-based company developing biologics on its Spirulina expression platform, said the Bill & Melinda Gates Foundation has tripled its funding commitment for Lumen's low-cost antibody therapeutics program.  Read More

Clinical data for June 13, 2018

Read More

FDA takes another crack at commercial speech controversy

If at first you don't succeed, you are not necessarily off the hook, a lesson the FDA has learned all too well in connection with the commercial speech problem. The agency released two new final guidances recently, one for payer communication and the other for general medical product communications, but a significant difference between the drafts and the final guidances is that the final guidances arrive with a nod of approval from two majority members of the House Energy and Commerce Committee, one of the key committees of jurisdiction where FDA issues are concerned. Read More

Samus moves anti-epichaperome into in myelofibrosis but eyes bigger prize in AD

On the heels of an FDA orphan drug designation for lead compound PU-H71 in myelofibrosis, privately held Samus Therapeutics Inc. moved the small molecule into a phase Ib dose-escalation study in patients with the bone marrow disorder. PU-H71 is designed to target the epichaperome, a protein complex present in more than half of the cancers tested by the company, a spinout of Memorial Sloan Kettering Cancer Center (MSKCC). Read More

Critics continue to question SCOTUS on patent eligibility

The U.S. Court of Appeals for the Federal Circuit said in a recent decision that the U.S. Supreme Court's handling of questions of patent eligibility has made the question unduly difficult, but the Federal Circuit's Judge Alan Lourie is hardly alone. Mark Lauroesch, executive director of the Intellectual Property Owners Association, told BioWorld that there was a time when the U.S. Patent and Trademark Office had issued patents for some undeserving applications, but that the pendulum has gone too far to the other side, and thus "we're now seeing the baby get thrown out with the bathwater." Read More

Brain sleepiness signature, links to memory identified

Birds do it. Bees do it. "Even jellyfish have this need," Qinghua Liu told BioWorld. Liu was referring, of course, to sleep, which he called "essentially... a black box, and one of the biggest mysteries of brain science." Read More

PROs needed to measure long-term toxicities of chronic cancer treatment: report

LONDON – New treatments for hematological cancers, including molecularly targeted therapies and immunotherapies, have increased life expectancy but also introduced a host of novel, chronic or cumulative toxicities that are not identified by current approaches to reporting adverse events. Read More

Stridebio steps up pace with $15.7M series A to support AAV vectors, moves toward clinic

Stridebio Inc., a company developing adeno-associated viral (AAV) vectors for in vivo gene therapies, has raised $15.7 million in an oversubscribed series A financing, money the company said will enable it to move multiple programs toward the clinic, with the first likely to reach proof of concept within the next six to nine months. Read More

Flex vexed in phase II bid; tolerability quit hits hard, exploring further options

Hopes for Flex Pharma Inc.'s phase II FLX-787 swirled down the drain – and so did the share price – after the company said clinical work is stopping because of oral tolerability concerns. Flex (NASDAQ:FLKS) ended Wednesday at $1.04, a loss of $3.14, or 75 percent. Read More

Regulatory actions for June 13, 2018

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe